<SEC-DOCUMENT>0001062993-21-005795.txt : 20210621
<SEC-HEADER>0001062993-21-005795.hdr.sgml : 20210621
<ACCEPTANCE-DATETIME>20210621060725
ACCESSION NUMBER:		0001062993-21-005795
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210617
FILED AS OF DATE:		20210621
DATE AS OF CHANGE:		20210621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IM Cannabis Corp.
		CENTRAL INDEX KEY:			0001792030
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40065
		FILM NUMBER:		211027109

	BUSINESS ADDRESS:	
		STREET 1:		1 ADELAIDE STREET EAST, UNIT 801
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5C 2V9
		BUSINESS PHONE:		416-256-4202

	MAIL ADDRESS:	
		STREET 1:		1 ADELAIDE STREET EAST, UNIT 801
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5C 2V9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html>

<head>
    <title>IM Cannabis Corp.: Form 6-K - Filed by newsfilecorp.com</title>
</head>

<body style="font-size:10pt; font-family:'Times New Roman';">
    <hr width="100%" size="3" color="black" noshade="noshade"><a name="page_1"></a>
    <p style="text-align: center;"><b><font size="5">UNITED STATES</font></b><br><b><font size="5">SECURITIES AND EXCHANGE COMMISSION</font></b><br>Washington, D.C. 20549<br><br><b><font size="5">Form 6-K</font></b><br><br><b>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</b><br><b>UNDER THE SECURITIES EXCHANGE ACT OF 1934</b></p>
    <p style="text-align: justify;">For the month of <b><u>June, 2021</u></b>.</p>
    <p style="margin-bottom: 0pt; text-align: justify;">Commission File Number: <u><b>001-40065</b></u></p>
    <p style="margin-top: 0pt; text-align: center;"><br><b><font size="5"><u>IM Cannabis Corp.</u></font></b><br>(Exact Name of Registrant as Specified in Charter)<br><br><u><b>Kibbutz Glil Yam, Central District, Israel 4690500</b></u><br>(Address of principal executive offices)</p>
    <p style="margin-bottom: 0pt; text-align: justify;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</p>
    <p style="margin-top: 0pt; text-align: justify;">Form 20-F&#160; &#9744;&#160; Form 40-F &#8864;</p>
    <p style="text-align: justify;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</p>
    <p style="text-align: justify;"><b>Note</b>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</p>
    <p style="text-align: justify;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</p>
    <p style="text-align: justify;"><b>Note</b>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_2"></a>
    <p style="text-align: center;"><b>SIGNATURE</b></p>
    <p style="text-indent: 36pt; text-align: justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
    <p style="text-indent: 36pt; text-align: justify;">&#160;</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
        <tr>
            <td style="width: 6.08%; padding: 0.75pt; vertical-align: middle;">
                <p>&#160;</p>
            </td>
            <td style="width: 44.56%; padding: 0.75pt; vertical-align: middle;">
                <p>&#160;</p>
            </td>
            <td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-bottom: 0.75pt; vertical-align: top;" colspan="2">
                <p><b>IM CANNABIS CORP.</b></p>
            </td>
            <td style="width: 7.6%; padding: 0.75pt; vertical-align: middle;">
                <p>&#160;</p>
            </td>
        </tr>
        <tr>
            <td style="width: 6.08%; padding: 0.75pt; vertical-align: middle;">
                <p>&#160;</p>
            </td>
            <td style="width: 44.56%; padding: 0.75pt; vertical-align: middle;">
                <p>&#160;</p>
            </td>
            <td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-bottom: 0.75pt; vertical-align: top;" colspan="2">
                <p>(Registrant)</p>
            </td>
            <td style="width: 7.6%; padding: 0.75pt; vertical-align: middle;">
                <p>&#160;</p>
            </td>
        </tr>
        <tr>
            <td style="width: 6.08%; padding: 0.75pt; vertical-align: middle;">
                <p>&#160;</p>
            </td>
            <td style="width: 44.56%; padding: 0.75pt; vertical-align: middle;">
                <p>&#160;</p>
            </td>
            <td style="width: 6.8%; padding: 0.75pt; vertical-align: middle;">
                <p>&#160;</p>
            </td>
            <td style="width: 34.96%; padding: 0.75pt; vertical-align: middle;">
                <p>&#160;</p>
            </td>
            <td style="width: 7.6%; padding-top: 0.75pt; padding-right: 0.75pt; padding-bottom: 0.75pt; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
            <td style="width: 6.08%; padding-top: 0.75pt; padding-right: 0.75pt; padding-bottom: 1.5pt; vertical-align: top;">
                <p>Date:</p>
            </td>
            <td style="width: 44.56%; padding-top: 0.75pt; padding-right: 0.75pt; padding-bottom: 1.5pt; vertical-align: top;">
                <p>June 21, 2021</p>
            </td>
            <td style="width: 6.8%; padding-top: 0.75pt; padding-right: 0.75pt; padding-bottom: 1.5pt; vertical-align: top;">
                <p>By:</p>
            </td>
            <td style="width: 34.96%; padding-top: 0.75pt; padding-right: 0.75pt; padding-bottom: 0.75pt; vertical-align: top;">
                <p><i>/s/ Oren Shuster</i></p>
            </td>
            <td style="width: 7.6%; padding: 0.75pt; vertical-align: middle;">
                <p>&#160;</p>
            </td>
        </tr>
        <tr>
            <td style="width: 6.08%; padding: 0.75pt; vertical-align: middle;">
                <p>&#160;</p>
            </td>
            <td style="width: 44.56%; padding: 0.75pt; vertical-align: middle;">
                <p>&#160;</p>
            </td>
            <td style="width: 6.8%; padding-top: 0.38pt; padding-right: 0.75pt; padding-bottom: 0.75pt; vertical-align: top; border-top: 0.75pt solid #000000;">
                <p>Name:</p>
            </td>
            <td style="width: 34.96%; padding-top: 0.38pt; padding-right: 0.75pt; padding-bottom: 0.75pt; vertical-align: top; border-top: 0.75pt solid #000000;">
                <p>Oren Shuster</p>
            </td>
            <td style="width: 7.6%; padding: 0.75pt; vertical-align: middle;">
                <p>&#160;</p>
            </td>
        </tr>
        <tr>
            <td style="width: 6.08%; padding-top: 0.75pt; padding-right: 0.75pt; padding-bottom: 0.75pt; vertical-align: top;">
                <p>&#160;</p>
            </td>
            <td style="width: 44.56%; padding-top: 0.75pt; padding-right: 0.75pt; padding-bottom: 0.75pt; vertical-align: top;">
                <p>&#160;</p>
            </td>
            <td style="width: 6.8%; padding-top: 0.75pt; padding-right: 0.75pt; padding-bottom: 0.75pt; vertical-align: top;">
                <p>Title:</p>
            </td>
            <td style="width: 34.96%; padding-top: 0.75pt; padding-right: 0.75pt; padding-bottom: 0.75pt; vertical-align: top;">
                <p>Chief Executive Officer and Director</p>
            </td>
            <td style="width: 7.6%; padding: 0.75pt; vertical-align: middle;">
                <p>&#160;</p>
            </td>
        </tr>
    </table>
    <br>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_3"></a>
    <p style="text-align: center;"><u><b>EXHIBIT INDEX</b></u></p>
    <p style="text-align: center;">&#160;</p>
    <table style="width: 100%; border-collapse: collapse; font-size: 10pt;" cellspacing="0" cellpadding="0">
        <tr>
            <td style="vertical-align: top; background-color: #eeeeee;">
                <p><a href="exhibit99-1.htm">99.1</a></p>
            </td>
            <td style="width: 90%; vertical-align: top; background-color: #eeeeee;">
                <p><a href="exhibit99-1.htm">News Release dated June 17, 2021</a></p>
            </td>
        </tr>
    </table>
    <br>
    <hr width="100%" size="5" color="black" noshade="noshade">
</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>

<head>
    <title>IM Cannabis Corp.: Exhibit 99.1 - Filed by newsfilecorp.com</title>
</head>

<body style="font-size:10pt; font-family:'Times New Roman';">
    <hr width="100%" size="3" color="black" noshade="noshade"><a name="page_1"></a>
    <p style="text-align: center;"><b>IM Cannabis Clinical Survey Confirms Effectiveness of Proprietary Strains in Alleviating <br>Symptoms of Seven Key Health Conditions</b></p>
    <p style="text-align: center;"><i>Conditions Evaluated Include Oncology, PTSD, Rheumatoid Arthritis, Chronic Pain, Insomnia, <br>Back Pain and Inflammatory Bowel Diseases</i></p>
    <p style="text-align: center;"><i>Conducted by Leading Contract Research Organization for Cannabis Research, Survey Covered <br>More Than 650 Patients Using FDA-Validated Questionnaires</i></p>
    <p style="text-align: justify;"><b>TORONTO, CANADA, and GLIL YAM, ISRAEL - June 17, 2021 -</b> IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC, CSE: IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational cannabis sectors with operations in Israel, Germany and Canada, today unveiled proprietary data from a clinical survey evaluating medicinal cannabis therapy. The patient survey, conducted by Medicanl Ltd. ("Medicanl"), an independent, international clinical research organization that specializes in cannabis research, and commissioned by IMC, reported the high effectiveness of seven IMC-branded medical cannabis strains in treating and alleviating symptoms of seven key health conditions in a clinical group of Israeli participants. The survey data will be used to help patients and doctors in medical markets all over the world customize cannabis-based therapies to best treat their diagnoses.</p>
    <p style="text-align: justify;">The clinical survey included 652 participants and covered the following conditions: neuropathic pain, rheumatoid arthritis, oncology, insomnia, back pain, inflammatory bowel diseases and PTSD. The goal was to evaluate the long-term efficacy of IMC's strains, including Roma, Ela, DQ, London, Pandora's Box, Paris and Tel Aviv (collectively, the "IMC Strains") on patients and their medical conditions using U.S. Food and Drug Administration-validated questionnaires.</p>
    <p style="margin-bottom: 0pt; text-align: justify;"><b>Key Findings</b>:</p>
    <ul style="padding-left: 0pt; margin-top: 0pt;" type="disc">
        <li style="margin-left: 27.6pt; padding-left: 8.4pt; text-align: justify;">Eighty-one percent of rheumatoid arthritis patients reported improved symptoms.</li>
        <li style="margin-left: 27.6pt; padding-left: 8.4pt; text-align: justify;">At least 60 percent of neuropathic pain patients reported improved symptoms.</li>
        <li style="margin-left: 27.6pt; padding-left: 8.4pt; text-align: justify;">At least 58 percent of back pain patients reported improved symptoms.</li>
        <li style="margin-left: 27.6pt; padding-left: 8.4pt; text-align: justify;">At least 42 percent of PTSD patients reported an improvement in their PTSD scale, which is measured by PCL-5, a validated questionnaire for quantifying PTSD symptom severity.</li>
        <li style="margin-left: 27.6pt; padding-left: 8.4pt; text-align: justify;">Thirty-eight percent of insomnia patients reported improved sleep quality based on the Pittsburgh Sleep Quality Index.</li>
        <li style="margin-left: 27.6pt; padding-left: 8.4pt; text-align: justify;">Sixty percent of oncology patients reported an improvement in overall health, as measured by the Patient Global Impression of Change scale.</li>
        <li style="margin-left: 27.6pt; padding-left: 8.4pt; text-align: justify;">IMC's Pandora's Box strain was effective in decreasing appetite in patients.</li>
        <li style="margin-left: 27.6pt; padding-left: 8.4pt; text-align: justify;">All seven IMC Strains improved sleep quality and increased patients' sense of calm, happiness and libido.</li>
        <li style="margin-left: 27.6pt; padding-left: 8.4pt; text-align: justify;">No adverse events were reported with respect to using IMC Strains.</li>
    </ul>
    <p style="text-align: justify;">"While medical cannabis' overall therapeutic benefits are well-known and documented, science is still just scratching the surface in terms of the global medical community fully understanding and realizing cannabinoids' potential in treating various health conditions," said Dr. David Meiri, Head of the Laboratory of Cancer Biology and Cannabinoid Research at the Technion, Israel Institute of Technology. "The availability of the data collected and extracted from these types of clinical surveys, which are based on FDA-validated questionnaires, despite not being peer-reviewed or derived from full-scale clinical trials, can help physicians and patients to better utilize and fine-tune the appropriate cannabis therapy for their specific medical conditions."&#160; &#160;</p>
    <p style="text-align: justify;">"As we have been in the medical cannabis space for over a decade, this invaluable data comes directly from patients, thanks to the Company's longstanding relationship with them," added Oren Shuster, CEO of IMC. "Rooted in hard science and research, IMC leverages this data to ensure that its patients across international markets are receiving high-quality cannabis products that are best-suited for their needs."</p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_2"></a>
    <p style="margin-bottom: 0pt; text-align: justify;"><b>Survey Methodology</b></p>
    <p style="margin-top: 0pt; text-align: justify;">The clinical survey was commissioned by IMC and conducted by an independent contract research organization, Medicanl, in 2020. The clinical survey included responses from 652 patients between the ages of 19 and 86 who used medicinal cannabis broadly (not just IMC Strains) for an average duration of over five years. The survey was conducted through online questionnaires validated by the FDA for the various indications and symptoms, along with demographic data collection in strict compliance with all privacy regulations through independent third-party surveyor, iPanel Ltd., which utilized responsive surveying methodologies. The survey covered seven IMC proprietary cannabis strains and assessed their impact on treating and alleviating symptoms of neuropathic pain, rheumatoid arthritis, oncology, insomnia, back pain, inflammatory bowel diseases and PTSD.</p>
    <p style="text-align: justify;">The findings of the survey have not undergone peer review, nor have they been submitted to any leading peer-reviewed medical journal. Additional data or studies may be necessary to confirm the reported findings.</p>
    <p style="margin-bottom: 0pt; text-align: justify;"><b>About IM Cannabis Corp.</b></p>
    <p style="margin-top: 0pt; text-align: justify;">IMC is an MCO in the medical and adult-use recreational cannabis sector, headquartered in Israel and with operations In Israel, Germany and Canada. Over the past decade, the Company believes that the IMC brand has become synonymous with quality and consistency in the Israeli medical cannabis market. The Company has also expanded its business to offer intellectual property-related services to the medical cannabis industry.</p>
    <p style="text-align: justify;">In Europe, IMC operates through Adjupharm GmbH ("<b>Adjupharm</b>"), a German-based subsidiary and EU GMP-certified medical cannabis processor and distributor. IMC's European presence is augmented by strategic alliances with various pan-European EU-GMP cultivators and distributors to capitalize on the increased demand for medical cannabis products in Europe and bring the IMC brand and its product portfolio to European patients.</p>
    <p style="text-align: justify;">In Canada, IMC operates through Trichome JWC Acquisition Corp. ("<b>JWC</b>"). JWC is a licensed producer located in Kitchener, Ontario, selling cannabis flower, pre-rolls, hash and kief in the Canadian recreational cannabis market under the JWC and Wagners brands. JWC operates with high standards for providing clean, consistent, aeroponically-grown premium cannabis products to medical patients and the adult-use market throughout Canada and the world. On March 31, 2021, IMC entered into a definitive agreement to acquire MYM Nutraceuticals Inc. ("<b>MYM</b>") and its licensed producer subsidiary, Highland Grow Inc. This transaction, if completed, will reinforce IMC's goal of being a leading global premium cannabis producer and purveyor.</p>
    <p style="margin-bottom: 0pt; text-align: justify;"><b>Disclaimer for Forward-Looking Statements</b></p>
    <p style="margin-top: 0pt; text-align: justify;"><i>This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities laws (collectively, "<b>forward-looking information</b>"). Forward-looking information are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking information in this press release includes, without limitation, statements relating to the use of the clinical survey data by doctors and patients and the global medical community's future understanding and realization of medical cannabis' potential in treating various health conditions.</i></p>
    <p style="text-align: justify;"><i>Developing forward-looking information involves reliance on several assumptions and considerations of certain risks and uncertainties, some of which are specific to IMC and others that apply to the industry generally. The risk factors and uncertainties that could cause actual results to differ materially from the anticipated results or expectations expressed in this press release, include without limitation,</i> <i>any determination that</i> <i>the results of the clinical survey were due to one or more factors other then medical cannabis,</i> <i>future scientific studies on the efficacy of medical cannabis and peer review of the clinical survey findings.</i></p>
    <hr style="page-break-after: always; text-align: center;" width="100%" size="5" color="black" noshade="noshade"><a name="page_3"></a>
    <p style="text-align: justify;"><i>Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.</i></p>
    <p style="margin-bottom: 0pt; text-align: justify;"><b>For more information</b>:</p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">Oren Shuster</p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">CEO, IM Cannabis</p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">+972-77-3603504</p>
    <p style="margin-top: 0pt; text-align: justify;">info@imcannabis.com</p>
    <p style="margin-bottom: 0pt; text-align: justify;">Caitlin Kasunich</p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">Media Relations - U.S.</p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">+1 212-896-1241</p>
    <p style="margin-top: 0pt; text-align: justify;">ckasunich@kcsa.com</p>
    <p style="margin-bottom: 0pt; text-align: justify;">Gal Wilder</p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">Media Relations - Canada</p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">+1 416-602-4092</p>
    <p style="margin-top: 0pt; text-align: justify;">gwilder@cohnwolfe.ca</p>
    <p style="margin-bottom: 0pt; text-align: justify;">Elizabeth Barker</p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">Investor Relations</p>
    <p style="margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">+1 212-896-1203</p>
    <p style="margin-top: 0pt; text-align: justify;">ebarker@kcsa.com</p>
    <hr width="100%" size="5" color="black" noshade="noshade">
</body>

</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
